Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in Diabetic Nephropathy (CREDENCE)
NCT02065791Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of canagliflozin in diabetic nephropathy (DN), sponsored by Janssen Pharmaceutical. Started Feb 2014; status: completed.
02
Drugs
canagliflozin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02065791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065791.